This underscores the importance of addressing the mental and emotional aspects of eating alongside the physiological changes induced by GLP-1 medications
Contact us today or schedule an appointment online
Dual GLP-1/GIP receptor agonists possess distinct pharmacodynamic and metabolic profiles, and long-term oncological safety data for these agents remain limited
Tirzepatide (Mounjaro), a dual GIP/GLP-1 receptor agonist approved for type 2 diabetes in the UK, has a similar adverse effect profile to other GLP-1 medications
The review highlighted D-Ribose, often paired with Coenzyme Q10, as a highly promising therapeutic intervention that deserves rigorous further study
During the first four weeks, most patients use the red pen at the 0.25 mg setting, allowing the body to adjust to the medication